Europe Hemophilia Market Size, Share & Industry Trends Analysis Report By Distribution Channel, By Type (Hemophilia A, Hemophilia B), By Treatment Type (Prophylaxis, On-demand, and Cure), By Therapy, By Country and Growth Forecast, 2023 - 2030

The Europe Hemophilia Market would witness market growth of 5.7% CAGR during the forecast period (2023-2030).

The market is expanding as a result of a number of causes, including the rising prevalence of hemophilia, supportive government initiatives, and increased research and development for the creation of novel medicines. The growing target demographic, higher diagnostic rates, more people being diagnosed with the condition, and an increase in preventative therapy for hemophilia are all factors that support market expansion.

Due to the requirement for more clotting factors or a different type of clotting factor, treating bleeding episodes becomes incredibly challenging, and the expense of care for a person with an inhibitor can soar. Inhibitors frequently cause increased joint disease and other bleeding-related issues that lower the quality of life.

The European Commission has granted BioMarin's ROCTAVIANTM (valoctocogene roxaparvovec) gene therapy conditional marketing authorization for the management of severe hemophilia A. The therapy is specifically developed for adult patients that don't have a history of Factor VIII inhibitors and with no detectable antibodies to adeno-associated virus serotype 5 (AAV5). Additionally, the EC agreed with the European Medicines Agency's (EMA) proposal that Roctavian keep its orphan medicine status, allowing it a 10-year window of market exclusivity. Therefore, similar efforts and developments in the coming years will propel the market's growth.

The Germany market dominated the Europe Hemophilia Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,114.3 million by 2030. The UK market is exhibiting a CAGR of 4.8% during (2023 - 2030). Additionally, The France market would experience a CAGR of 6.5% during (2023 - 2030).

Based on Distribution Channel, the market is segmented into Specialty Pharmacies, and Hospital Pharmacies. Based on Type, the market is segmented into Hemophilia A, Hemophilia B, and Others. Based on Treatment Type, the market is segmented into Prophylaxis, On-demand, and Cure. Based on Therapy, the market is segmented into Factor Replacement Therapy (Recombinant Factor Concentrates, and Plasma-derived Factor Concentrates), Desmopressin & Fibrin Sealants, and Gene Therapy & Monoclonal Antibodies. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

Free Valuable Insights: The Worldwide Hemophilia Market is Projected to reach USD 18.3 Billion by 2030, at a CAGR of 6.2%

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Takeda Pharmaceutical Company Limited, CSL Limited (CSL Behring), Pfizer, Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, Octapharma AG, BioMarin Pharmaceutical Inc., Swedish Orphan Biovitrum AB (Investor AB) and Sanofi S.A.

Scope of the Study

Market Segments Covered in the Report:

By Distribution Channel

• Specialty Pharmacies
• Hospital Pharmacies

By Type

• Hemophilia A
• Hemophilia B
• Others

By Treatment Type

• Prophylaxis
• On-demand
• Cure

By Therapy

• Factor Replacement Therapy
  • Recombinant Factor Concentrates
  • Plasma-derived Factor Concentrates
• Desmopressin & Fibrin Sealants
• Gene Therapy & Monoclonal Antibodies

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Key Market Players

List of Companies Profiled in the Report:

• Takeda Pharmaceutical Company Limited
• CSL Limited (CSL Behring)
• Pfizer, Inc.
• Bayer AG
• F.Hoffmann-La Roche Ltd.
• Novo Nordisk A/S
• Octapharma AG
• BioMarin Pharmaceutical Inc.
• Swedish Orphan Biovitrum AB (Investor AB)
• Sanofi S.A.

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Hemophilia Market, by Distribution Channel
1.4.2 Europe Hemophilia Market, by Type
1.4.3 Europe Hemophilia Market, by Treatment Type
1.4.4 Europe Hemophilia Market, by Therapy
1.4.5 Europe Hemophilia Market, by Country
1.5 Methodology for the research

Chapter 2. Market At a Glance
2.1 Key Highlights

Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints

Chapter 4. Competition Analysis - Global
4.1 KBV Cardinal Matrix
4.2 Recent Industry Wide Strategic Developments
4.2.1 Partnerships, Collaborations and Agreements
4.2.2 Product Launches and Product Expansions
4.2.3 Acquisition and Mergers
4.2.4 Trials and Approvals
4.3 Top Winning Strategies
4.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
4.3.2 Key Strategic Move: (Product Launches and Product Expansions : 2017, Jun – 2021, Jun) Leading Players
4.4 Porter Five Forces Analysis

Chapter 5. Europe Hemophilia Market by Distribution Channel
5.1 Europe Specialty Pharmacies Market by Country
5.2 Europe Hospital Pharmacies Market by Country

Chapter 6. Europe Hemophilia Market by Type
6.1 Europe Hemophilia A Market by Country
6.2 Europe Hemophilia B Market by Country
6.3 Europe Others Market by Country

Chapter 7. Europe Hemophilia Market by Treatment Type
7.1 Europe Prophylaxis Market by Country
7.2 Europe On-demand Market by Country
7.3 Europe Cure Market by Country

Chapter 8. Europe Hemophilia Market by Therapy
8.1 Europe Factor Replacement Therapy Market by Country
8.2 Europe Hemophilia Market by Factor Replacement Therapy Type
8.2.1 Europe Recombinant Factor Concentrates Market by Country
8.2.2 Europe Plasma-derived Factor Concentrates Market by Country
8.3 Europe Desmopressin & Fibrin Sealants Market by Country
8.4 Europe Gene Therapy & Monoclonal Antibodies Market by Country

Chapter 9. Europe Hemophilia Market by Country
9.1 Germany Hemophilia Market
9.1.1 Germany Hemophilia Market by Distribution Channel
9.1.2 Germany Hemophilia Market by Type
9.1.3 Germany Hemophilia Market by Treatment Type
9.1.4 Germany Hemophilia Market by Therapy
9.1.4.1 Germany Hemophilia Market by Factor Replacement Therapy Type
9.2 UK Hemophilia Market
9.2.1 UK Hemophilia Market by Distribution Channel
9.2.2 UK Hemophilia Market by Type
9.2.3 UK Hemophilia Market by Treatment Type
9.2.4 UK Hemophilia Market by Therapy
9.2.4.1 UK Hemophilia Market by Factor Replacement Therapy Type
9.3 France Hemophilia Market
9.3.1 France Hemophilia Market by Distribution Channel
9.3.2 France Hemophilia Market by Type
9.3.3 France Hemophilia Market by Treatment Type
9.3.4 France Hemophilia Market by Therapy
9.3.4.1 France Hemophilia Market by Factor Replacement Therapy Type
9.4 Russia Hemophilia Market
9.4.1 Russia Hemophilia Market by Distribution Channel
9.4.2 Russia Hemophilia Market by Type
9.4.3 Russia Hemophilia Market by Treatment Type
9.4.4 Russia Hemophilia Market by Therapy
9.4.4.1 Russia Hemophilia Market by Factor Replacement Therapy Type
9.5 Spain Hemophilia Market
9.5.1 Spain Hemophilia Market by Distribution Channel
9.5.2 Spain Hemophilia Market by Type
9.5.3 Spain Hemophilia Market by Treatment Type
9.5.4 Spain Hemophilia Market by Therapy
9.5.4.1 Spain Hemophilia Market by Factor Replacement Therapy Type
9.6 Italy Hemophilia Market
9.6.1 Italy Hemophilia Market by Distribution Channel
9.6.2 Italy Hemophilia Market by Type
9.6.3 Italy Hemophilia Market by Treatment Type
9.6.4 Italy Hemophilia Market by Therapy
9.6.4.1 Italy Hemophilia Market by Factor Replacement Therapy Type
9.7 Rest of Europe Hemophilia Market
9.7.1 Rest of Europe Hemophilia Market by Distribution Channel
9.7.2 Rest of Europe Hemophilia Market by Type
9.7.3 Rest of Europe Hemophilia Market by Treatment Type
9.7.4 Rest of Europe Hemophilia Market by Therapy
9.7.4.1 Rest of Europe Hemophilia Market by Factor Replacement Therapy Type

Chapter 10. Company Profiles
10.1 Swedish Orphan Biovitrum AB (Investor AB)
10.1.1 Company Overview
10.1.2 Financial Analysis
10.1.3 Segmental and Regional Analysis
10.1.4 Research & Development Expenses
10.1.5 SWOT Analysis
10.2 Takeda Pharmaceutical Company Limited
10.2.1 Company Overview
10.2.2 Financial Analysis
10.2.3 Regional Analysis
10.2.4 Research & Development Expense
10.2.5 Recent strategies and developments:
10.2.5.1 Trials and Approvals:
10.2.5.2 Product Launches and Product Expansions:
10.3 Pfizer, Inc.
10.3.1 Company Overview
10.3.2 Financial Analysis
10.3.3 Regional & Segmental Analysis
10.3.4 Research & Development Expense
10.3.4.1 Partnerships, Collaborations, and Agreements:
10.3.4.2 Acquisition and Mergers:
10.4 CSL Limited (CSL Behring)
10.4.1 Company Overview
10.4.2 Financial Analysis
10.4.3 Segmental and Regional Analysis
10.4.4 Research & Development Expense
10.4.5 Recent strategies and developments:
10.4.5.1 Trials and Approvals:
10.4.5.2 Acquisition and Mergers:
10.4.6 SWOT Analysis
10.5 Octapharma AG
10.5.1 Company Overview
10.5.2 Financial Analysis
10.5.3 Research & Development Expenses
10.5.4 Recent strategies and developments:
10.5.4.1 Trials and Approvals:
10.5.5 SWOT Analysis
10.6 Bayer AG
10.6.1 Company Overview
10.6.2 Financial Analysis
10.6.3 Segmental and Regional Analysis
10.6.4 Research & Development Expense
10.6.5 Recent strategies and developments:
10.6.5.1 Partnerships, Collaborations, and Agreements:
10.6.5.2 Acquisition and Mergers:
10.6.6 SWOT Analysis
10.7 F. Hoffmann-La Roche Ltd.
10.7.1 Company Overview
10.7.2 Financial Analysis
10.7.3 Segmental and Regional Analysis
10.7.4 Research & Development Expense
10.7.5 SWOT Analysis
10.8 Novo Nordisk A/S
10.8.1 Company Overview
10.8.2 Financial Analysis
10.8.3 Segmental & Regional Analysis
10.8.4 Research & Development Expenses
10.8.5 Recent strategies and developments:
10.8.5.1 Partnerships, Collaborations, and Agreements:
10.8.5.2 Product Launches and Product Expansions:
10.8.5.3 Acquisition and Mergers:
10.8.6 SWOT Analysis
10.9 BioMarin Pharmaceutical Inc.
10.9.1 Company Overview
10.9.2 Financial Analysis
10.9.3 Regional Analysis
10.9.4 Research & Development Expenses
10.9.5 Recent strategies and developments:
10.9.5.1 Trials and Approvals:
10.9.6 SWOT Analysis
10.10. Sanofi S.A.
10.10.1 Company Overview
10.10.2 Financial Analysis
10.10.3 Segmental and Regional Analysis
10.10.4 Research & Development Expense
10.10.5 Recent strategies and developments:
10.10.5.1 Trials and Approvals:

TABLE 1 Europe Hemophilia Market, 2019 - 2022, USD Million
TABLE 2 Europe Hemophilia Market, 2023 - 2030, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Hemophilia Market
TABLE 4 Product Launches And Product Expansions– Hemophilia Market
TABLE 5 Acquisition and Mergers– Hemophilia Market
TABLE 6 Trials and Approvals– Hemophilia Market
TABLE 7 Europe Hemophilia Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 8 Europe Hemophilia Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 9 Europe Specialty Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 10 Europe Specialty Pharmacies Market by Country, 2023 - 2030, USD Million
TABLE 11 Europe Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 12 Europe Hospital Pharmacies Market by Country, 2023 - 2030, USD Million
TABLE 13 Europe Hemophilia Market by Type, 2019 - 2022, USD Million
TABLE 14 Europe Hemophilia Market by Type, 2023 - 2030, USD Million
TABLE 15 Europe Hemophilia A Market by Country, 2019 - 2022, USD Million
TABLE 16 Europe Hemophilia A Market by Country, 2023 - 2030, USD Million
TABLE 17 Europe Hemophilia B Market by Country, 2019 - 2022, USD Million
TABLE 18 Europe Hemophilia B Market by Country, 2023 - 2030, USD Million
TABLE 19 Europe Others Market by Country, 2019 - 2022, USD Million
TABLE 20 Europe Others Market by Country, 2023 - 2030, USD Million
TABLE 21 Europe Hemophilia Market by Treatment Type, 2019 - 2022, USD Million
TABLE 22 Europe Hemophilia Market by Treatment Type, 2023 - 2030, USD Million
TABLE 23 Europe Prophylaxis Market by Country, 2019 - 2022, USD Million
TABLE 24 Europe Prophylaxis Market by Country, 2023 - 2030, USD Million
TABLE 25 Europe On-demand Market by Country, 2019 - 2022, USD Million
TABLE 26 Europe On-demand Market by Country, 2023 - 2030, USD Million
TABLE 27 Europe Cure Market by Country, 2019 - 2022, USD Million
TABLE 28 Europe Cure Market by Country, 2023 - 2030, USD Million
TABLE 29 Europe Hemophilia Market by Therapy, 2019 - 2022, USD Million
TABLE 30 Europe Hemophilia Market by Therapy, 2023 - 2030, USD Million
TABLE 31 Europe Factor Replacement Therapy Market by Country, 2019 - 2022, USD Million
TABLE 32 Europe Factor Replacement Therapy Market by Country, 2023 - 2030, USD Million
TABLE 33 Europe Hemophilia Market by Factor Replacement Therapy Type, 2019 - 2022, USD Million
TABLE 34 Europe Hemophilia Market by Factor Replacement Therapy Type, 2023 - 2030, USD Million
TABLE 35 Europe Recombinant Factor Concentrates Market by Country, 2019 - 2022, USD Million
TABLE 36 Europe Recombinant Factor Concentrates Market by Country, 2023 - 2030, USD Million
TABLE 37 Europe Plasma-derived Factor Concentrates Market by Country, 2019 - 2022, USD Million
TABLE 38 Europe Plasma-derived Factor Concentrates Market by Country, 2023 - 2030, USD Million
TABLE 39 Europe Desmopressin & Fibrin Sealants Market by Country, 2019 - 2022, USD Million
TABLE 40 Europe Desmopressin & Fibrin Sealants Market by Country, 2023 - 2030, USD Million
TABLE 41 Europe Gene Therapy & Monoclonal Antibodies Market by Country, 2019 - 2022, USD Million
TABLE 42 Europe Gene Therapy & Monoclonal Antibodies Market by Country, 2023 - 2030, USD Million
TABLE 43 Europe Hemophilia Market by Country, 2019 - 2022, USD Million
TABLE 44 Europe Hemophilia Market by Country, 2023 - 2030, USD Million
TABLE 45 Germany Hemophilia Market, 2019 - 2022, USD Million
TABLE 46 Germany Hemophilia Market, 2023 - 2030, USD Million
TABLE 47 Germany Hemophilia Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 48 Germany Hemophilia Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 49 Germany Hemophilia Market by Type, 2019 - 2022, USD Million
TABLE 50 Germany Hemophilia Market by Type, 2023 - 2030, USD Million
TABLE 51 Germany Hemophilia Market by Treatment Type, 2019 - 2022, USD Million
TABLE 52 Germany Hemophilia Market by Treatment Type, 2023 - 2030, USD Million
TABLE 53 Germany Hemophilia Market by Therapy, 2019 - 2022, USD Million
TABLE 54 Germany Hemophilia Market by Therapy, 2023 - 2030, USD Million
TABLE 55 Germany Hemophilia Market by Factor Replacement Therapy Type, 2019 - 2022, USD Million
TABLE 56 Germany Hemophilia Market by Factor Replacement Therapy Type, 2023 - 2030, USD Million
TABLE 57 UK Hemophilia Market, 2019 - 2022, USD Million
TABLE 58 UK Hemophilia Market, 2023 - 2030, USD Million
TABLE 59 UK Hemophilia Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 60 UK Hemophilia Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 61 UK Hemophilia Market by Type, 2019 - 2022, USD Million
TABLE 62 UK Hemophilia Market by Type, 2023 - 2030, USD Million
TABLE 63 UK Hemophilia Market by Treatment Type, 2019 - 2022, USD Million
TABLE 64 UK Hemophilia Market by Treatment Type, 2023 - 2030, USD Million
TABLE 65 UK Hemophilia Market by Therapy, 2019 - 2022, USD Million
TABLE 66 UK Hemophilia Market by Therapy, 2023 - 2030, USD Million
TABLE 67 UK Hemophilia Market by Factor Replacement Therapy Type, 2019 - 2022, USD Million
TABLE 68 UK Hemophilia Market by Factor Replacement Therapy Type, 2023 - 2030, USD Million
TABLE 69 France Hemophilia Market, 2019 - 2022, USD Million
TABLE 70 France Hemophilia Market, 2023 - 2030, USD Million
TABLE 71 France Hemophilia Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 72 France Hemophilia Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 73 France Hemophilia Market by Type, 2019 - 2022, USD Million
TABLE 74 France Hemophilia Market by Type, 2023 - 2030, USD Million
TABLE 75 France Hemophilia Market by Treatment Type, 2019 - 2022, USD Million
TABLE 76 France Hemophilia Market by Treatment Type, 2023 - 2030, USD Million
TABLE 77 France Hemophilia Market by Therapy, 2019 - 2022, USD Million
TABLE 78 France Hemophilia Market by Therapy, 2023 - 2030, USD Million
TABLE 79 France Hemophilia Market by Factor Replacement Therapy Type, 2019 - 2022, USD Million
TABLE 80 France Hemophilia Market by Factor Replacement Therapy Type, 2023 - 2030, USD Million
TABLE 81 Russia Hemophilia Market, 2019 - 2022, USD Million
TABLE 82 Russia Hemophilia Market, 2023 - 2030, USD Million
TABLE 83 Russia Hemophilia Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 84 Russia Hemophilia Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 85 Russia Hemophilia Market by Type, 2019 - 2022, USD Million
TABLE 86 Russia Hemophilia Market by Type, 2023 - 2030, USD Million
TABLE 87 Russia Hemophilia Market by Treatment Type, 2019 - 2022, USD Million
TABLE 88 Russia Hemophilia Market by Treatment Type, 2023 - 2030, USD Million
TABLE 89 Russia Hemophilia Market by Therapy, 2019 - 2022, USD Million
TABLE 90 Russia Hemophilia Market by Therapy, 2023 - 2030, USD Million
TABLE 91 Russia Hemophilia Market by Factor Replacement Therapy Type, 2019 - 2022, USD Million
TABLE 92 Russia Hemophilia Market by Factor Replacement Therapy Type, 2023 - 2030, USD Million
TABLE 93 Spain Hemophilia Market, 2019 - 2022, USD Million
TABLE 94 Spain Hemophilia Market, 2023 - 2030, USD Million
TABLE 95 Spain Hemophilia Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 96 Spain Hemophilia Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 97 Spain Hemophilia Market by Type, 2019 - 2022, USD Million
TABLE 98 Spain Hemophilia Market by Type, 2023 - 2030, USD Million
TABLE 99 Spain Hemophilia Market by Treatment Type, 2019 - 2022, USD Million
TABLE 100 Spain Hemophilia Market by Treatment Type, 2023 - 2030, USD Million
TABLE 101 Spain Hemophilia Market by Therapy, 2019 - 2022, USD Million
TABLE 102 Spain Hemophilia Market by Therapy, 2023 - 2030, USD Million
TABLE 103 Spain Hemophilia Market by Factor Replacement Therapy Type, 2019 - 2022, USD Million
TABLE 104 Spain Hemophilia Market by Factor Replacement Therapy Type, 2023 - 2030, USD Million
TABLE 105 Italy Hemophilia Market, 2019 - 2022, USD Million
TABLE 106 Italy Hemophilia Market, 2023 - 2030, USD Million
TABLE 107 Italy Hemophilia Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 108 Italy Hemophilia Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 109 Italy Hemophilia Market by Type, 2019 - 2022, USD Million
TABLE 110 Italy Hemophilia Market by Type, 2023 - 2030, USD Million
TABLE 111 Italy Hemophilia Market by Treatment Type, 2019 - 2022, USD Million
TABLE 112 Italy Hemophilia Market by Treatment Type, 2023 - 2030, USD Million
TABLE 113 Italy Hemophilia Market by Therapy, 2019 - 2022, USD Million
TABLE 114 Italy Hemophilia Market by Therapy, 2023 - 2030, USD Million
TABLE 115 Italy Hemophilia Market by Factor Replacement Therapy Type, 2019 - 2022, USD Million
TABLE 116 Italy Hemophilia Market by Factor Replacement Therapy Type, 2023 - 2030, USD Million
TABLE 117 Rest of Europe Hemophilia Market, 2019 - 2022, USD Million
TABLE 118 Rest of Europe Hemophilia Market, 2023 - 2030, USD Million
TABLE 119 Rest of Europe Hemophilia Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 120 Rest of Europe Hemophilia Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 121 Rest of Europe Hemophilia Market by Type, 2019 - 2022, USD Million
TABLE 122 Rest of Europe Hemophilia Market by Type, 2023 - 2030, USD Million
TABLE 123 Rest of Europe Hemophilia Market by Treatment Type, 2019 - 2022, USD Million
TABLE 124 Rest of Europe Hemophilia Market by Treatment Type, 2023 - 2030, USD Million
TABLE 125 Rest of Europe Hemophilia Market by Therapy, 2019 - 2022, USD Million
TABLE 126 Rest of Europe Hemophilia Market by Therapy, 2023 - 2030, USD Million
TABLE 127 Rest of Europe Hemophilia Market by Factor Replacement Therapy Type, 2019 - 2022, USD Million
TABLE 128 Rest of Europe Hemophilia Market by Factor Replacement Therapy Type, 2023 - 2030, USD Million
TABLE 129 Key Information – Swedish Orphan Biovitrum AB
TABLE 130 Key Information – Takeda Pharmaceutical Company Limited
TABLE 131 Key Information – Pfizer, Inc.
TABLE 132 Key Information – CSL Limited
TABLE 133 Key Information – Octapharma AG
TABLE 134 Key Information – Bayer AG
TABLE 135 Key Information – F. Hoffmann-La Roche Ltd.
TABLE 136 Key Information – Novo Nordisk A/S
TABLE 137 Key Information – BioMarin Pharmaceutical Inc.
TABLE 138 Key Information – Sanofi S.A.

List of Figures
FIG 1 Methodology for the research
FIG 2 Europe Hemophilia Market, 2019 - 2030, USD Million
FIG 3 Key Factors Impacting the Hemophilia Market
FIG 4 KBV Cardinal Matrix
FIG 5 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 6 Key Strategic Move: (Product Launches and Product Expansions : 2017, Jun – 2021, Jun) Leading Players
FIG 7 Porter’s Five Forces Analysis –Hemophilia Market
FIG 8 Europe Hemophilia Market share by Distribution Channel, 2022
FIG 9 Europe Hemophilia Market share by Distribution Channel, 2030
FIG 10 Europe Hemophilia Market by Distribution Channel, 2019 - 2030, USD Million
FIG 11 Europe Hemophilia Market share by Type, 2022
FIG 12 Europe Hemophilia Market share by Type, 2030
FIG 13 Europe Hemophilia Market by Type, 2019 - 2030, USD Million
FIG 14 Europe Hemophilia Market share by Treatment Type, 2022
FIG 15 Europe Hemophilia Market share by Treatment Type, 2030
FIG 16 Europe Hemophilia Market by Treatment Type, 2019 - 2030, USD Million
FIG 17 Europe Hemophilia Market share by Therapy, 2022
FIG 18 Europe Hemophilia Market share by Therapy, 2030
FIG 19 Europe Hemophilia Market by Therapy, 2019 - 2030, USD Million
FIG 20 Europe Hemophilia Market share by Country, 2022
FIG 21 Europe Hemophilia Market share by Country, 2030
FIG 22 Europe Hemophilia Market by Country, 2019 - 2030, USD Million
FIG 23 SWOT Analysis: Swedish Orphan Biovitrum AB
FIG 24 SWOT Analysis: CSL Limited
FIG 25 SWOT Analysis: Octapharma AG
FIG 26 SWOT Analysis: Bayer AG
FIG 27 SWOT Analysis: F. Hoffmann-La Roche Ltd.
FIG 28 Recent strategies and developments: Novo Nordisk A/S
FIG 29 SWOT Analysis: Novo Nordisk A/S
FIG 30 SWOT Analysis: BioMarin Pharmaceutical Inc.